FDA approves two strengths of a new leuprolide acetate formulation
Links shared publicly online about this topic.
- 67total visits
FDA approves two strengths of a new leuprolide acetate formulation
Two strengths of leuprolide acetate for depot suspension in a 3-month formulation have been approved by the FDA for treatment of central precoci
View full resource at endocrinetoday.com
Tags: Puberty, Precocious Puberty, Prostate Cancer Medication, FDA, Lupron, Leuplin
Most Recently Shared on August 16, 2011 at 8:36 pm By:
#FDA approves two strengths of a new leuprolide acetate formulation for precocious puberty http://t.co/0n6b5tA
FDA approves two new strengths of Lupron Depot-PED for central precocious puberty
news-medical.net — “Abbott announced today that the U.S. Food and Drug Administration has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).” View full resource at news-medical.net
Most Recently Shared on August 17, 2011 at 5:01 am By:
Epilepsy News: FDA approves two new strengths of Lupron Depot-PED for central precocious puberty: Abbott announc... http://t.co/LRtww2p
Advertisement
